Ronac Mamtani, MD, MSCE
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Office: 2156627606
Fax: (215) 349-8551
Fax: (215) 349-8551
Email:
ronac.mamtani@uphs.upenn.edu
ronac.mamtani@uphs.upenn.edu
Education:
BS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Permanent linkBS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Selected Publications
Chow RD, Sedhom R, Mamtani R.: Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer. JAMA Oncol Nov 2025.Litt HK, Mamtani R, Chow RD.: Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction. Urol Oncol Nov 2025.
Kong AM, Andrean D, Khan S, Choi J, Mamtani R, Parikh R, Jaksa A, Campbell U.: Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2. J Comp Eff Res Oct 2025.
Chow RD, Mamtani R.: Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma. Urol Oncol 43(10): 597, Oct 2025.
Meng Y, Zhang S, Aout M, Babcock A, Li H, Lai Y, Brand-Wiita S, Notinger S, Bavle A, Mamtani R.: Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States. J Med Econ Oct 2025.
Squires P, Cook EE, Song Y, Wang CY, Jiang AX, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R.: Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis. J Manag Care Spec Pharm Sep 2025.
Chow RD, Mamtani R.: Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma. Clin Genitourin Cancer Aug 2025.
Parikh RB, Ulloa-Pérez E, Kurian M, Hubbard R, Joffe S, Lynch HF, Mamtani R.: Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies. JAMA Netw Open 8(7): e2520726, Jul 2025.
Lian Y, Voruganti T, Lu J, Long Q, Mamtani R.: Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates. JAMA Netw Open 8(7): e2519524, Jul 2025.
Reibel JB, Sun LL, Parikh RB, Mahmud N, Martin LP, Hubbard RA, Mamtani R.: Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer. J Natl Cancer Inst 117(6): 1276-1278, Jun 2025.